Related Experiment Videos
Total androgen ablation: European experience. The EORTC GU Group
L Denis1, P Smith, J L Carneiro de Moura
1Department of Urology, A.Z. Middelheim, Antwerp, Belgium.
The Urologic Clinics of North America
|February 1, 1991
Summary
Zoladex plus flutamide delays cancer progression but does not improve survival compared to orchiectomy in advanced prostate cancer patients. Survival after progression may even be shorter with this combination therapy.
Area of Science:
- Oncology
- Urology
Background:
- Advanced prostate cancer treatment often involves androgen deprivation therapy.
- Comparing combination therapy (Zoladex plus flutamide) with orchiectomy is crucial for optimizing patient outcomes.
Purpose of the Study:
- To evaluate the impact of Zoladex plus flutamide versus orchiectomy on progression and survival in advanced prostate cancer.
- To assess the overall survival and time to progression in patients receiving these treatments.
Main Methods:
- A comparative study analyzing time to progression (subjective, objective, first progression) and survival (all-cause and cancer-specific mortality).
- Inclusion of data from Bone Scan Committee reviews and pain response assessments.
Main Results:
- Zoladex plus flutamide significantly delayed time to progression compared to orchiectomy.
- No significant difference in overall survival or cancer-specific survival was detected between the two treatment groups.
- Survival duration after progression appeared shorter in the Zoladex plus flutamide group.
Conclusions:
- While Zoladex plus flutamide delays progression, it does not offer a survival benefit over orchiectomy for advanced prostate cancer.
- Challenges in defining response criteria and patient heterogeneity necessitate further research for tailored treatment strategies.